Miguel Varela
GROUP LEADER - DRUG DELIVERY
Miguel leads a research group at the Institute of Development and Regenerative Medicine and connects AI agents with the physical world, translating their digital power into practical outcomes that enable future visionary scientists and entrepreneurs.
His research interests focus on:
#1 discovery of novel therapeutic targets.
#2 the development of new delivery systems for RNA therapy.
#3 studying the interface of the immune system with the pathology of neuromuscular and cardiac diseases.
Recent publications
Design, validation, and functional impact of oligonucleotides for multigene silencing in Alzheimer's disease.
Journal article
Woffindale C. et al, (2026), Mol Ther Nucleic Acids, 37
Enhanced muscle uptake of chemically optimized miR-23b antisense oligonucleotides as lead compounds for myotonic dystrophy type 1.
Journal article
González-Martínez I. et al, (2026), Am J Hum Genet
Exon skipping peptide-conjugated morpholinos downregulate dynamin 2 to rescue centronuclear myopathy.
Journal article
Moschovaki-Filippidou F. et al, (2025), Brain, 148, 4495 - 4507
miR-107 represses DMPK and is sequestered by CUG repeats triggering the MSI2/miR-7 pathogenesis axis in myotonic dystrophy.
Journal article
Moreno N. et al, (2025), Mol Ther Nucleic Acids, 36
Dysregulated MEG3 in Myotonic Dystrophy 1: nuclear retention, pathological role, and therapeutic correction by antisense conjugates
Preprint
Seoane-Miraz D. et al, (2025)